New $2.7m contract in progressive supranuclear palsy with a global pharmaceutical company

IXICO plc (AIM: IXI), the digital technologies company serving neuroscience, today announces that it has signed an additional new contract with an existing global pharmaceutical customer. The contract value is $2.7m, over a seven year term, to commence immediately.

IXICO will provide its technology enabled imaging services in a clinical trial of a novel therapeutic to treat people with progressive supranuclear palsy (‘PSP’), a rare neurodegenerative disease.

By |2018-01-30T09:15:35+00:0030 January 2018|Contracts|